Praxis(US:PRAX)2026-02-19 13:02Financial Performance - The company reported net losses of $303.3 million and $182.8 million for the years ended December 31, 2025 and 2024, respectively, with an accumulated deficit of $1.1 billion as of December 31, 2025[504]. - The company reported a net cash used in operating activities of $249.1 million for the year ended December 31, 2025, primarily due to a net loss of $303.3 million[554]. - For the year ended December 31, 2025, net cash provided by financing activities was $702.2 million, mainly from the October 2025 public offering[557]. - The company has not recorded any U.S. federal or state income tax benefits due to uncertainty in realizing benefits from net losses incurred[530]. - As of December 31, 2025, the company had federal and state net operating loss carryforwards available to offset future taxable income, beginning to expire in 2031[531]. Funding and Capital - The company has raised approximately $161.6 million from a public offering in January 2024, selling 3,802,025 shares at a price of $35.50 per share[508]. - The company raised $1.8 billion in aggregate cash proceeds from various stock offerings since inception, with cash, cash equivalents, and marketable securities totaling $926.1 million as of December 31, 2025[540]. - In 2024, the company issued and sold 1,614,975 shares under the March 2024 Sales Agreement, generating net proceeds of $113.1 million after expenses[545]. - In April 2024, the company completed a public offering of 3,849,558 shares at $56.50 per share, resulting in total net proceeds of approximately $216.0 million[546]. - In 2025, the company issued 1,351,689 shares under the amended March 2024 Sales Agreement, yielding net proceeds of $83.3 million[547]. - The company anticipates needing substantial additional funds to achieve its business objectives, with potential risks related to market volatility affecting capital access[565]. Research and Development - The company is advancing multiple clinical programs, including the ENERGY program for vormatrigine, with topline results expected in 2026 and 2027[498]. - The company has submitted New Drug Applications (NDAs) for ulixacaltamide and relutrigine to the FDA, with commercial preparations underway for both products[496][497]. - The company expects to announce topline results for the EMBRAVE Part A study of elsunersen in the first half of 2026 and is currently enrolling in the EMBRAVE3 pivotal clinical trial[500]. - The company has three earlier stage novel antisense oligonucleotides (ASOs) with preclinical proof of mechanism, with development candidates expected to be nominated in the first half of 2026[501]. - Total research and development expenses increased by $114.7 million to $267.1 million in 2025, primarily driven by a $91.9 million increase in expenses related to the Cerebrum™ platform[535]. - Research and development expenses for the Cerebrum™ platform reached $185.5 million in 2025, up from $93.6 million in 2024[535]. - Research and development expenses include personnel-related costs, materials, and external costs for preclinical and clinical trials, all of which are expensed as incurred[576]. - The company estimates accrued and prepaid research and development expenses based on open contracts, service performance, and invoicing schedules, which may lead to adjustments in reported expenses[577]. - Payments to vendors for research services may exceed the level of services provided, resulting in prepayments, and are influenced by factors such as patient enrollment and milestone completion[578]. - The company anticipates significant expenses as it prepares for the commercialization of its product candidates and expands its research and development activities[504]. - The company expects substantial increases in expenses related to ongoing research and development activities, particularly for preclinical and clinical trials[559]. Expenses - General and administrative expenses rose by $2.8 million to $59.1 million in 2025, mainly due to increased professional fees and software costs[536]. - Personnel-related expenses, including stock-based compensation, increased to $58.7 million in 2025 from $43.4 million in 2024[535]. - The company anticipates that general and administrative expenses may continue to rise as headcount increases to support growth in research and development activities[528]. Revenue and Collaboration - Collaboration revenue decreased to $0 in 2025 from $8.6 million in 2024 due to UCB exercising its option to in-license global development rights[534]. - Other income, net increased by $5.6 million to $22.9 million in 2025, attributed to higher interest income from cash and marketable securities[537]. Accounting and Compliance - The company prepares its consolidated financial statements in accordance with U.S. generally accepted accounting principles, requiring significant estimates and assumptions that may affect reported amounts of assets and liabilities[574]. - The company has reviewed recently issued accounting standards and determined that they will not have a material impact on its consolidated financial statements[579]. - The company is exposed to market risk related to interest rate changes, but an immediate change of 100 basis points would not materially impact its financial position due to the low risk profile of its portfolio[580]. Agreements and Obligations - The company has entered into various sales agreements, including a $250.0 million agreement in September 2025, raising $40.5 million from the sale of 403,947 shares[513]. - The company has a milestone payment obligation of $3.0 million to RogCon, contingent upon certain conditions being met[570]. - The company has entered into multiple agreements that may require future milestone and royalty payments based on product sales[571].